Treatment Patterns and Outcomes of Ovarian Cancer in Different Centres of Karachi

Perwasha  Kerio; Ghulam  Haider; Khalil Ahmed; Saima Zahoor; Hina Perveen; Muhammad Hayat

doi:10.51253/pafmj.v75iSUPPL-1.5677

Authors

Perwasha Kerio Jinnah Postgraduate Medical Center, Karachi Pakistan
Ghulam Haider Jinnah Postgraduate Medical Center, Karachi Pakistan
Khalil Ahmed Jinnah Postgraduate Medical Center, Karachi Pakistan
Saima Zahoor Jinnah Postgraduate Medical Center, Karachi Pakistan
Hina Perveen Jinnah Postgraduate Medical Center, Karachi Pakistan
Muhammad Hayat Jinnah Postgraduate Medical Center, Karachi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75iSUPPL-1.5677

Keywords:

Clinical Response, Ovarian Cancer, Partial Response, Pathological Complete Response, Surgery.

Abstract

Objective: To evaluate the treatment pattern i.e. either upfront surgery followed by adjuvant chemotherapy or upfront neoadjuvant chemotherapy followed by surgery and outcomes of advance ovarian cancer in different hospitals of Karachi.

Study Design: observational study

Place and Duration of Study: Oncology Department, Jinnah Postgraduate Medical Center, Karachi Pakistan, from March 2019-Sep 2020.

Methodology: All females of age 18-70 years with diagnosis of epithelial ovarian cancer (stage III-IV) and who had received chemotherapy or on chemotherapy in upfront or in adjuvant setting from another hospital and came to Jinnah Postgraduate Medical Center in mid of treatment due to exhaustion of financial resources, as ovarian cancer treatment costs high and oncology department Jinnah Postgraduate Medical Center provides free treatment.

Results: Of 170 patient, 119(70%) patients received adjuvant chemotherapy after surgery, while 51(30%) received neoadjuvant chemotherapy followed by surgery. Among 51 patients who received neoadjuvant (upfront) chemotherapy, 30(58.8%) had partial and 13(25.5%) had complete clinical response, whereas 42(82.4%) had partial and 9(17.6%) had complete pathological response. About 38(74.5%) had complete and 13(25.5%) had partial biochemical response. Each patient followed for one and half year to see recurrence rate. Patients who underwent surgery 45(48.4%) had recurrence, 38(40.9%) completed the treatment plan and 10(10.7%) died. In patients who underwent neoadjuvant chemotherapy 12(41.4%) showed recurrence, 11(37.9%) completed the treatment plan and 6(20.7%) died.

Conclusion: To date most of the centers in Karachi following the pattern of upfront surgery followed by adjuvant chemotherapy. More disease recurrences are seen in upfront surgery group....

Downloads

Download data is not yet available.

References

Basu P, De P, Mandal S, Ray K, Biswas J. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 2009; 46(1): 28-33. https://doi:10.4103/0019-509x.48592.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health. 2019; 11: 287-99. https://doi:10.2147/ijwh.s197604.

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4): 284-96. https://doi:10.3322/caac.21456.

OCRA. Ovarian cancer research alliance 2020 [cited 2020]. Available from: https://ocrahope.org/patients/about-ovarian-cancer/statistics/#:~:text=Age%20of%20Ovarian%20Cancer%20Diagnosis,from%20ovarian%20cancer%20is%2070.

Malik IA. A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan. J Pak Med Assoc. 2002; 52(4): 155-8.

Mostafa MF, El-etreby N, Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University. Alexandria Journal of Medicine. 2012; 48(4): 353-60. https://doi.org/10.1016/j.ajme.2012.07.001.

Martín-Cameán M, Delgado-Sánchez E, Piñera A, Diestro MD, De Santiago J, Zapardiel I. The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience. 2016; 10: 666. https://doi:10.3332/ecancer.2016.666.

Chishti U, Aziz AB. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women. J Pak Med Assoc. 2015; 65(3): 306-9.

Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, et al. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Radiology and oncology. 2018; 52(3): 307-19. https://doi:10.2478/raon-2018-0030.

Nakamura K, Kitahara Y, Nishimura T, Yamashita S, Kigure K, Ito I, et al. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer. World J Surg Oncol. 2020; 18(1): 200. https://doi:10.1186/s12957-020-01978-6.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer biology & medicine. 2017; 14(1): 9-32. https://doi:10.20892/j.issn.2095-3941.2016.0084.

Sarwar CM, Siddiqui N, Khokhar RA, Badar F. Epithelial ovarian cancer at a cancer hospital in a developing country. Asian Pac J Cancer Prev. 2006; 7(4): 595-8.

Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015; 16(6): 807-20. https://doi:10.1080/15384047.2015.1040960.

Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. J Gynecol Oncol. 2017; 28(4): e48-e. https://doi:10.3802/jgo.2017.28.e48.

Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia. 2016; 32(3): 298-310. https://doi:10.3109/02656736.2016.1149233.

Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R, Svedas E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer. 2006; 6: 153. https://doi:10.1186/1471-2407-6-153.

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018; 81(1): 17-38. https://doi:10.1007/s00280-017-3501-8.

Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol. 2014; 6(6): 293-304. https://doi:10.1177/1758834014544891.